The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|July 7, 2011
Dr. Schuchter on the Next Steps in Melanoma Research
Author(s)Lynn M. Schuchter, MD
Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research
Advertisement
Lynn M. Schuchter, MD, division chief of hematology-oncology at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia on the next steps in melanoma research which include combination of targeted therapies, combination with immunotherapies, and developing therapies for earlier stages of melanoma.
Advertisement
Related to this article
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
3
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
4
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
5